legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o
Company profile
Ticker
LEGN
Exchange
Website
CEO
Ying Huang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
LEGN stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
22 Apr 24
6-K
Current report (foreign)
16 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
29 Mar 24
F-3ASR
Automatic shelf registration (foreign)
19 Mar 24
20-F
2023 FY
Annual report (foreign)
19 Mar 24
6-K
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study
15 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
11 Mar 24
6-K
Current report (foreign)
23 Feb 24
Latest ownership filings
SC 13G/A
BlackRock Inc.
5 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
144/A
Notice of proposed sale of securities (amended)
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 202 |
Opened positions | 25 |
Closed positions | 18 |
Increased positions | 70 |
Reduced positions | 68 |
13F shares | Current |
---|---|
Total value | 5.74 tn |
Total shares | 281.12 mm |
Total puts | 226.89 k |
Total calls | 167.50 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
GenScript Biotech | 174.50 mm | $0.00 |
Hillhouse Capital Management | 20.27 mm | $0.00 |
FMR | 15.91 mm | $1.07 tn |
T. Rowe Price | 9.69 mm | $650.31 bn |
Hillhouse Capital Advisors | 6.44 mm | $432.34 bn |
Ra Capital Management | 6.26 mm | $420.80 bn |
BLK Blackrock | 4.62 mm | $310.39 bn |
Capital World Investors | 2.39 mm | $160.39 bn |
Paradigm Biocapital Advisors | 2.03 mm | $136.05 bn |
Polar Capital | 1.87 mm | $125.75 bn |
News
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
23 Apr 24
Legend Biotech Announces Carvykti Approved By The European Commission For Second-Line Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
22 Apr 24
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
19 Apr 24
Analyst Ratings For Legend Biotech
17 Apr 24
Scotiabank Upgrades Legend Biotech to Sector Outperform, Maintains Price Target to $65
17 Apr 24
Press releases
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
22 Apr 24
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
11 Apr 24
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
5 Apr 24
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
19 Mar 24
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
15 Mar 24